GB002 is in clinical development for PAH (NCT03926793).

Figure 5. GB002 significantly decreased pulmonary arteriolar muscularization and improved disease biomarkers in the SU5416 hypoxia rat model

A. Impact of GB002 on vascular remodeling. Vessels were defined as non-muscular or muscular (> 90% smooth muscle layer circumference). 50 vessels per lobe (n = 3 per group) were analyzed by a blinded histopathologist. Data shown as fold change ± SEM, *p < 0.05, **p < 0.005, ****p < 0.0001 vs vehicle.

B. Effects on lung BMPR2 protein expression on day 49. Data shown as fold change ± SEM. *p < 0.05 vs vehicle.

C. Circulating plasma levels of NT-proBNP on Day 49. Data shown as mean ± SD, *p < 0.05, **p < 0.005, ****p < 0.0001 vs vehicle.

CONCLUSION

• Localized lung delivery of GB002 inhibits PDGFR signaling and restores BMPR2 expression in vivo, translating to improved cardiopulmonary hemodynamics and disease reverse remodeling in the SU5416/H rat PAH model.

• GB002 is in clinical development for PAH (NCT03926793).

ACKNOWLEDGEMENTS

Funded by GB002, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. The authors gratefully acknowledge IPS Therapeutique (Canada) and ITR (Canada) for support of in vivo studies.

DISCLOSURES

All authors are employed by Gossamer Bio, Inc.